BioMarin Pharmaceutical Inc. Overview
Pro stress-test →BioMarin Pharmaceutical is a biotechnology company that engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions. Founded in 1997, the company has a proven track record of innovation, with eight commercial therapies and a strong clinical and preclinical pipeline.
Strategic Profile
Pro stress-test →The company agreed to acquire Amicus Therapeutics for $14.50 per share, valuing the deal at approximately $4.8 billion, with the transaction expected to close in Q2 2026. The acquisition adds marketed therapies Galafold and Pombiliti + Opfolda that generated $599 million in net product revenue over the past four quarters, positioning BioMarin as a more diversified rare disease player.
Competitive Landscape
Pro stress-test →BioMarin serves specialty pharmacies, hospitals, government agencies, and distributors in the rare disease space. Key competitors in rare disease biotechnology include Ultragenyx Pharmaceutical, Alnylam Pharmaceuticals, Regeneron, Biogen, and Ionis Pharmaceuticals. BioMarin's differentiation lies in its focused pipeline of genetically-defined rare disease therapies and established commercial infrastructure.
Industry Context
BioMarin Pharmaceutical Inc. operates in Biotechnology - Rare Disease Therapeutics.
Key facts
Founded: 1997 · Headquarters: San Rafael, US · Employees: N/A · Revenue: $3.3B · Market cap: N/A